Open AccessAssociation Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering
Author(s) -
Eliano Pio Navarese,
Jennifer G. Robinson,
Mariusz Kowalewski,
Michalina Kołodziejczak,
Felicita Andreotti,
Kevin P. Bliden,
Udaya S. Tantry,
Jacek Kubica,
Paolo Raggi,
Paul A. Gurbel
Publication year - 2018
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2018.2525
Subject(s) - medicine , ezetimibe , relative risk , randomized controlled trial , adverse effect , meta analysis , mace , cholesterol , confidence interval , myocardial infarction , percutaneous coronary intervention
Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom